심낭염 치료제 시장 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2025-2034년)

The Global Pericarditis Drugs Market was valued at USD 4.1 billion in 2024 and is estimated to grow at a CAGR of 6.2% to reach USD 7.4 billion by 2034. Rising cardiovascular disease rates across the globe are significantly driving demand for targeted anti-inflammatory therapies. These medications are widely used for managing both acute and chronic forms of pericarditis by minimizing pain and inflammation around the heart. With advancements in medical technology and the growing use of drug regimens, more effective treatments are being introduced. Expanding healthcare infrastructure in developing nations and a rise in cardiac health awareness are also accelerating market growth.

Studies indicate a higher incidence of pericarditis among men, which is linked to hormonal factors such as elevated testosterone levels that amplify inflammatory responses to viral infections. As hospitals and cardiology centers increasingly adopt advanced drug therapies, the demand for specialized treatment options continues to climb. Several pharmaceutical companies are pushing for innovation and broader access to pericarditis medications, ensuring the market maintains its momentum across both established and emerging regions.

The acute pericarditis segment held a 46.1% share in 2024. This segment is growing steadily due to a rise in cases, better diagnostic tools, and more streamlined care pathways. Increasing focus on early detection in cardiovascular health has prompted a stronger preference for managing acute symptoms quickly and effectively, rather than allowing conditions to advance to chronic stages. Acute care strategies are gaining attention for their ability to alleviate symptoms, control inflammation, and prevent further complications. These approaches often rely on non-invasive diagnostics and first-line medications, especially anti-inflammatory agents, which help reduce the need for extended hospital stays or complex monitoring, making them ideal for both advanced and resource-limited healthcare systems.

The oral formulations segment accounted for a 58.2% share in 2024. This dominance stems from their superior performance in delivering consistent systemic drug absorption and their compatibility with commonly prescribed anti-inflammatory treatments such as colchicine and NSAIDs. Oral administration offers significant advantages, including ease of use, better patient adherence, and cost savings. Compared to injectable drugs, oral medications are simpler to use in outpatient settings and reduce the burden on the healthcare infrastructure. Patients also tend to favor oral options due to their convenience and the ability to follow treatment plans at home.

North America Pericarditis Drugs Market held a 46.6% share in 2024. This strong performance is fueled by higher awareness of cardiovascular disorders and significant investment in medical innovation. The region benefits from some of the highest healthcare spending per capita, offering widespread access to advanced diagnostics and specialized treatment. Continued adherence to updated clinical guidelines ensures evidence-based use of therapies like colchicine and immune-modulating agents. The robust presence of medical infrastructure and leading pharmaceutical research hubs in this region also supports a fast-paced commercialization cycle for emerging pericarditis drugs.

Key pharmaceutical companies actively involved in the Global Pericarditis Drugs Market include Sun Pharmaceuticals, Bayer, Dr. Reddy's Laboratories, Kiniksa Pharmaceuticals, Teva Pharmaceuticals, AstraZeneca, Novartis, Zydus Cadila, Takeda Pharmaceuticals, Merck, Pfizer, Cipla, Eli Lilly, and Fosun Pharma. Companies competing in the pericarditis drugs landscape are focusing on developing novel drug formulations and expanding their product portfolios through strategic research and development. Many are leveraging partnerships with healthcare institutions and research centers to advance clinical trials and optimize treatment efficacy. Emphasis is placed on expanding access through global distribution channels, particularly in emerging markets where awareness and diagnosis are improving. Firms are also adopting lifecycle management strategies, including the development of generic versions and combination therapies, to extend product viability. Integration of advanced drug delivery systems and digital adherence tools enhances treatment outcomes and patient compliance.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumption and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional
  • 2.2.2 Type trends
  • 2.2.3 Drug class trends
  • 2.2.4 Route of administration trends
  • 2.2.5 Gender trends
  • 2.2.6 End use trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Value addition at each stage
  • 3.1.3 Factor affecting the value chain
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of cardiovascular diseases
    • 3.2.1.2 Rising geriatric population
    • 3.2.1.3 Growing awareness among healthcare professionals
    • 3.2.1.4 Expansion of hospital and specialty care networks
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of novel therapies
    • 3.2.2.2 Regulatory and clinical trial hurdles
  • 3.2.3 Market opportunities
    • 3.2.3.1 Emerging markets with rising healthcare access
    • 3.2.3.2 Shift toward personalized and targeted therapies
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Future market trends
• 3.6 Pipeline analysis
• 3.7 Patent landscape
• 3.8 Technology and innovation landscape
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Acute pericarditis
• 5.3 Recurrent pericarditis
• 5.4 Chronic pericarditis
• 5.5 Other types

Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Nonsteroidal anti-inflammatory drugs
• 6.3 Colchicine
• 6.4 IL-1 inhibitors/biologics
• 6.5 Other drug classes

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Parenteral

Chapter 8 Market Estimates and Forecast, By Gender, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Male
• 8.3 Female

Chapter 9 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 Hospitals and clinics
• 9.3 Homecare settings
• 9.4 Other end use

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 AstraZeneca
• 11.2 Bayer
• 11.3 Cipla
• 11.4 Dr. Reddy's Laboratories
• 11.5 Eli Lilly
• 11.6 Fosun Pharma
• 11.7 Kiniksa Pharmaceuticals
• 11.8 Merck
• 11.9 Novartis
• 11.10 Pfizer
• 11.11 Sun Pharmaceuticals
• 11.12 Takeda Pharmaceuticals
• 11.13 Teva Pharmaceuticals
• 11.14 Zydus Cadila